Caricamento...

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Adv Pract Oncol
Autori principali: Myers, Rebecca A., Wirth, Scott, Williams, Sherry, Kiel, Patrick J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Harborside Press 2018
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6347084/
https://ncbi.nlm.nih.gov/pubmed/30719396
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !